Clinical trials: Biochemical Recurrence
Prostate Cancer Recurrent
Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer
This Phase II trial will enroll approximately 180 adult male patients with an earlier histologic diagnosis of prostatic adenocarcinoma and a biochemical recurrence (BCR) within 3 years of radical prostatectomy (RP) or definitive…
- Trial name
- BRaVac (NCT04114825)
- Testing
- RV001V
- Where
- 36 sites in United States, Belgium and 5 more
- Volunteers
- 180 people
- Sponsor
- RhoVac APS
Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate
RYZ711 Diagnostic Platform Study
This is a Phase 1/2 multicenter, multi-cohort imaging study to evaluate the safety, tolerability, and diagnostic performance of RYZ711 positron emission tomography/computed tomography (PET/CT) in men with histologically confirmed…
- Conditions
- Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Trial name
- NCT07862582
- Testing
- RYZ711, PSMA PET/CT
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- RayzeBio, Inc.
Prostate Cancer, High-risk Biochemical Recurrence
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
The main objective of this study is to evaluate the safety and tolerability of xaluritamig monotherapy in adult participants with high-risk biochemical recurrent (BCR) nonmetastatic castration-sensitive prostate cancer (nmCSPC).
- Conditions
- Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer
- Trial name
- NCT06555796
- Testing
- Xaluritamig
- Where
- 11 sites in United States, Australia
- Volunteers
- 50 people
- Sponsor
- Amgen
Prostate Cancer Recurrent, Biochemical Recurrent Prostate Cancer
MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer
This is an open label trial to assess the efficacy of MBM-02 (Tempol) as a treatment for patients diagnosed with prostate cancer in biochemical recurrence.
- Trial name
- NCT04876755
- Testing
- MBM-02
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Matrix Biomed, Inc.
Biochemical Recurrence of Malignant Neoplasm of Prostate
64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate…
- Trial name
- SABRE (NCT05407311)
- Testing
- 64Cu-SAR-BBN
- Where
- 8 sites in United States
- Volunteers
- 53 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostate Cancer Recurrent
F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence
This study evaluates the diagnostic performance and safety of F-18-PSMA-1007 and F-18-Fluorocholine PET/CT imaging in patients with suspected recurrence of prostate cancer after previous definitive treatment.
- Trial name
- NCT04102553
- Testing
- F-18-PSMA-1007, F-18-Fluorocholine
- Where
- 6 sites in France
- Volunteers
- 200 people
- Sponsor
- ABX advanced biochemical compounds GmbH
Prostate Cancer
Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer
This was an open-label, multi-centre, uncontrolled, exploratory trial with a duration of 12 months in two cohorts. The trial aimed to investigate Degarelix as a second-line hormonal treatment in Prostate Cancer patients who…
- Trial name
- NCT00738673
- Testing
- degarelix
- Where
- 15 sites in Germany
- Volunteers
- 37 people
- Sponsor
- Ferring Pharmaceuticals
Prostatic Neoplasms, Prostate Cancer
Study of Diagnostic Performance of [18F]CTT1057 in BCR
The current study aimed at evaluating the diagnostic performance of [18F]CTT1057 as a PET imaging agent for detection and localization of Prostate specific membrane antigen (PSMA) positivity in patients diagnosed of biochemical…
- Conditions
- Prostatic Neoplasms, Prostate Cancer, Recurrence
- Trial name
- GuidePath (NCT04838613)
- Testing
- [18F]CTT1057, [68Ga]Ga-PSMA-11
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 190 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer Metastatic
68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)
This was an open-label, multicenter, single dose, Phase I/II study to evaluate the safety and tolerability of a single administration of 3 mega Becquerel (MBq)/kg, but not less than 150 MBq and not more than 250 MBq, of…
- Trial name
- PROfind (NCT03490032)
- Testing
- [68Ga]-PSMA-R2
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Advanced Accelerator Applications
Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer
68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
This is a prospective, open-label, single-arm, multicenter bridging study in Chinese patients with prostate cancer. This multicenter study is planned to be conducted in patients with biochemical recurrence (BCR) of elevated PSA…
- Conditions
- Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma
- Trial name
- NCT05847348
- Testing
- 68Ga-PSMA-11, PET/CT or PET/MRI
- Where
- 8 sites in China
- Volunteers
- 110 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer
- Conditions
- Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy, Prostate Cancer Recurrent, Prostate Cancer Patients Who Have Brachytherapy Seed Implant
- Trial name
- AMPLIFY (NCT06970847)
- Testing
- 64Cu-SAR-bisPSMA
- Where
- 22 sites in United States, Australia
- Volunteers
- 220 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Prostate Cancer
Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
This is a multi-centre, Phase 1/2, open-label clinical trial of the VTP-850 prime-boost immunotherapeutic in men with biochemical recurrence after definitive local therapy for prostate cancer.
- Trial name
- NCT05617040
- Testing
- ChAdOx1-PCAQ, MVA-PCAQ
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Barinthus Biotherapeutics
Prostate Cancer
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men with Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
- Trial name
- NCT06604442
- Testing
- flotufolastat (18F), piflufolastat (18F)
- Where
- 9 sites in United States
- Volunteers
- 62 people
- Sponsor
- Blue Earth Diagnostics
Prostate Cancer
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival…
- Trial name
- EvoPAR-PR02 (NCT06952803)
- Testing
- Saruparib, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
- Where
- 346 sites in United States, Argentina and 26 more
- Volunteers
- 700 people
- Sponsor
- AstraZeneca
Ovarian Cancer, Genitourinary (GU) Tumors
A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy
This is an open-label, randomized, phase 2 study of an IDO inhibitor, INCB024360 (epacadostat) versus tamoxifen in biochemical recurrent only ovarian cancer patients following complete remission with first-line chemotherapy.
- Trial name
- NCT01685255
- Testing
- Epacadostat, tamoxifen
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 83 people
- Sponsor
- Incyte Corporation